Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact

Kyle Blankenship

The use of adeno-associated viruses (AAV) as delivery vehicles for gene therapeutics has been riddled with safety concerns for years — a fact Sarepta knows well …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Re­cent­ly stung by AAV, Sarep­ta dives a lit­tle deep­er in­to non-vi­ral de­liv­ery with newest li­cens­ing pact

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact